Nouatin, Odilon
Ibáñez, Javier
Fendel, Rolf http://orcid.org/0000-0003-4716-0311
Ngoa, Ulysse A.
Lorenz, Freia-Raphaella
Dejon-Agobé, Jean-Claude
Edoa, Jean Ronald
Flügge, Judith
Brückner, Sina
Esen, Meral
Theisen, Michael
Hoffman, Stephen L.
Moutairou, Kabirou
Luty, Adrian J. F.
Lell, Bertrand
Kremsner, Peter G.
Adegnika, Ayola A.
Mordmüller, Benjamin
Funding for this research was provided by:
DZIF (TTU03.801, TTU 03.702, TTU 03.703)
Universitätsklinikum Tübingen
Article History
Received: 25 October 2021
Accepted: 23 April 2022
First Online: 17 June 2022
Declarations
:
: The original study was approved by the Comité National d’Ethique de la Recherche (CNER) of Gabon, under the reference N°004/2015/SG/P. The trial was performed according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines and the Declaration of Helsinki and is registered with the Pan-African Clinical Trials Registry (trial number PACTR201503001038304). Written informed consent was received from all study participants before inclusion into the clinical trial.
: Not applicable.
: As CEO of Sanaria Inc., SLH has a potential conflict of interest. All other authors declared that they have no competing interests.